American Journal of Cardiology
Volume 104, Issue 4 , Pages 459-463 , 15 August 2009

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

  • Ole Faergeman, MD, DMSc

      Affiliations

    • Department of Medicine and Cardiology A, Århus University Hospital, Århus, Denmark
    • Corresponding Author InformationCorresponding author: Tel: 45-7527-9072; Fax: 45-7527-9072
    • ,
  • Ingar Holme, PhD

      Affiliations

    • Center of Preventive Medicine, Ullevål University Hospital, Oslo, Norway
    • ,
  • Rana Fayyad, PhD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • Sonal Bhatia, MD

      Affiliations

    • Pfizer, Inc., New York, New York
    • ,
  • Scott M. Grundy, MD, PhD

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • John J.P. Kastelein, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    • ,
  • John C. LaRosa, MD

      Affiliations

    • State University of New York Health Science Center, Brooklyn, New York
    • ,
  • Mogens Lytken Larsen, MD, DMSc

      Affiliations

    • Department of Medicine and Cardiology A, Århus University Hospital, Århus, Denmark
    • ,
  • Christina Lindahl, MD

      Affiliations

    • Pfizer, Sweden, Sollentuna, Sweden
    • ,
  • Anders G. Olsson, MD, PhD

      Affiliations

    • Department of Internal Medicine, Faculty of Health Sciences, University Hospital, Linköping, Sweden
    • ,
  • Matti J. Tikkanen, MD, PhD

      Affiliations

    • Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland
    • ,
  • David D. Waters, MD

      Affiliations

    • San Francisco General Hospital, San Francisco, California
    • ,
  • Terje R. Pedersen, MD, PhD

      Affiliations

    • Center of Preventive Medicine, Ullevål University Hospital, Oslo, Norway
    • ,
  • Steering Committees of the IDEAL and TNT Trials

Received 13 January 2009 ,Revised 11 April 2009 ,Accepted 11 April 2009.

References 

  1. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445
  2. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  3. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. Am J Cardiol. 2004;94:720–724
  4. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol. 2004;93:154–158
  5. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470–475
  6. McGowan MW, Artiss JD, Strandbergh DR, Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983;29:538–542
  7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  8. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B (III. Comparability of apolipoprotein A-I values by use of international reference material). Clin Chem. 1993;39:773–781
  9. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B (IV. Comparability of apolipoprotein B values by use of International Reference Material). Clin Chem. 1994;40:586–592
  10. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–730
  11. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029–1036
  12. Carlson LA, Bottiger LE. Risk factors for ischaemic heart disease in men and women (Results of the 19-year follow-up of the Stockholm Prospective Study). Acta Med Scand. 1985;218:207–211
  13. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions (The association between triglyceride and coronary heart disease). N Engl J Med. 1980;302:1383–1389
  14. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–219
  15. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size (Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution). Arterioscler Thromb. 1994;14:707–720
  16. Parhofer KG, Barrett PH. Thematic review series: patient-oriented research (What we have learned about VLDL and LDL metabolism from human kinetics studies). J Lipid Res. 2006;47:1620–1630
  17. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007;298:309–316
  18. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298:299–308
  19. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375–2414
  20. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421

 The IDEAL and TNT studies were sponsored by Pfizer, Inc., New York, New York.

PII: S0002-9149(09)00910-2

doi: 10.1016/j.amjcard.2009.04.008

American Journal of Cardiology
Volume 104, Issue 4 , Pages 459-463 , 15 August 2009

Article Tools

* Image Usage & Resolution